Emerging differences between 5-HT3 receptor antagonists.
A brief review is presented of some recently described 5-HT3 receptor antagonists. These antagonists are primarily targeted for use as anti-emetics. However, evidence is emerging that there are differences in their basic pharmacology. This evidence is reviewed in terms of the selectivity of the antagonists in binding studies and also of their efficacy in emesis and gastric emptying. The possibility that these differences may translate into meaningful clinical differences between the available 5-HT3 receptor antagonists in their use as anti-emetics is also discussed.
Marr
H E
HE
SmithKline Beecham Pharmaceuticals, Medicinal Research Centre, Harlow, Essex, UK.
Davey
P T
PT
Bartlett
A J
AJ
D000818:Animals; D000932:Antiemetics / Q000494:pharmacology*; D005769:Gastrointestinal Motility / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008787:Metoclopramide / Q000494:pharmacology; D012702:Serotonin Antagonists; D014839:Vomiting / Q000503:physiopathology / Q000517:prevention & control
D000932:Antiemetics; D012702:Serotonin Antagonists; D008787:Metoclopramide